Top

Published in:

16-10-2021 | Bronchial Asthma | Sleep Breathing Physiology and Disorders • Review

Association between YKL-40 and asthma: a systematic meta-analysis

Authors: Yihan Jin, Jie Song, Fang Xu, Di Zhang, Jinfang He, Jiakun Zheng, Yanan Zhang, Jintong Li, Yikun Guo, Mengjiao Xu, Xiangfeng Yu, Yanbin Liu, Qinghua Liu, Jun Yan

Published in: Sleep and Breathing | Issue 3/2022

Abstract

Purpose

Many studies have shown that chitinase-3-like protein 1 (CHI3L1), also known as YKL-40, is associated with asthma. The purpose of this meta-analysis was to evaluate the role of serum YKL-40 in the diagnosis and differential diagnosis of asthma, severity grading, and determination of disease state.

Methods

The PubMed, Ovid, and Cochrane databases were searched. A total of 17 articles involving 5696 subjects were included in this meta-analysis.

Results

The results showed that the level of YKL-40 was significantly higher in asthmatic patients than in the normal group regardless of age and residential location, and increased with severity and acute exacerbation (p < 0.05). YKL-40 levels were significantly different between chronic obstructive pulmonary disease (COPD) and asthma, and also between asthma-COPD overlap syndrome (ACO) and asthma (p < 0.05).

Conclusion

YKL-40 may act as a potential serological marker for the diagnosis of asthma, assessment of severity, indicator of the disease state, and differential diagnosis of COPD, ACO, and asthma.

Boot RG, Blommaart EF, Swart E et al (2001) Identification of a novel acidic mammalian chitinase distinct from chitotriosidase[J]. J Biol Chem 276(9):6770–6778PubMedCrossRef

Dickey BF (2007) Exoskeletons and exhalation[J]. N Engl J Med 357(20):2082–2084PubMedCrossRef

Leung TF, Ching KW, Sy HY et al (2010) CHIA confers susceptibility to childhood eczema[J]. Br J Dermatol 163(6):1360–1362PubMedCrossRef

Lin HW, Chiang YC, Sun NY et al (2019) CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells[J]. Endocr Relat Cancer 26(1):73–88PubMedCrossRef

Furuhashi K, Suda T, Nakamura Y et al (2010) Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis[J]. Respir Med 104(8):1204–1210PubMedCrossRef

Kuepper M, Bratke K, Virchow JC (2008) Chitinase-like protein and asthma[J]. N Engl J Med 358(10):1073–1075, 1075PubMedCrossRef

Wang J, Lv H, Luo Z et al (2018) Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD[J]. Respir Res 19(1):47PubMedPubMedCentralCrossRef

Specjalski K, Chelminska M, Jassem E (2015) YKL-40 protein correlates with the phenotype of asthma[J]. Lung 193(2):189–194PubMedPubMedCentralCrossRef

Gomez JL, Crisafi GM, Holm CT et al (2015) Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40[J]. J Allergy Clin Immunol 136(1):51–58PubMedPubMedCentralCrossRef

10.

Kim SH, Choi H, Yoon MG et al (2015) Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype[J]. Ann Allergy Asthma Immunol 114(3):208–213PubMedCrossRef

11.

Chupp GL, Lee CG, Jarjour N et al (2007) A chitinase-like protein in the lung and circulation of patients with severe asthma[J]. N Engl J Med 357(20):2016–2027PubMedCrossRef

12.

Tang H, Fang Z, Sun Y et al (2010) YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E[J]. Eur Respir J 35(4):757–760PubMedCrossRef

13.

Specjalski K, Jassem E (2011) YKL-40 protein is a marker of asthma[J]. J Asthma 48(8):767–772PubMedCrossRef

14.

Konradsen JR, James A, Nordlund B et al (2013) The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma[J]. J Allergy Clin Immunol 132(2):328–335PubMedCrossRef

15.

Kim HR, Jun CD, Lee KS et al (2012) Levels of YKL-40 in pleural effusions and blood from patients with pulmonary or pleural disease[J]. Cytokine 58(3):336–343PubMedCrossRef

16.

Duru S, Yuce G, Ulasli SS et al (2013) The relationship between serum YKL-40 levels and severity of asthma[J]. Iran J Allergy Asthma Immunol 12(3):247–253PubMed

17.

Tsai Y, Ko Y, Huang M et al (2014) CHI3L1 polymorphisms associate with asthma in a Taiwanese population[J]. BMC Med Genet 15:86PubMedPubMedCentralCrossRef

18.

Shirai T, Hirai K, Gon Y et al (2019) Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap[J]. J Allergy Clin Immunol Pract 7(1):134–145PubMedCrossRef

19.

Han SS, Lee WH, Hong Y et al (2016) Comparison of serum biomarkers between patients with asthma and with chronic obstructive pulmonary disease[J]. J Asthma 53(6):583–588PubMedCrossRef

20.

El BN, Osman HM, Abdelaal AA et al (2018) Increased expression of serum periostin and YKL40 in children with severe asthma and asthma exacerbation[J]. J Investig Med 66(8):1102–1108CrossRef

21.

Gon Y, Maruoka S, Ito R et al (2017) Utility of serum YKL-40 levels for identification of patients with asthma and COPD[J]. Allergol Int 66(4):624–626PubMedCrossRef

22.

Santos CB, Davidson J, Covar RA et al (2014) The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children[J]. Ann Allergy Asthma Immunol 113(3):263–266PubMedCrossRef

23.

James AJ, Reinius LE, Verhoek M et al (2016) Increased YKL-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med 193(2):131–142PubMedCrossRef

24.

Rathcke CN, Johansen JS, Vestergaard H (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance[J]. Inflamm Res 55(2):53–59PubMedCrossRef

25.

Bara I, Ozier A, Girodet PO et al (2012) Role of YKL-40 in bronchial smooth muscle remodeling in asthma[J]. Am J Respir Crit Care Med 185(7):715–722PubMedCrossRef

26.

Tang H, Sun Y, Shi Z et al (2013) YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-kappaB pathways, causing bronchial smooth muscle proliferation and migration[J]. J Immunol 190(1):438–446PubMedCrossRef

27.

Iwata T, Kuwajima M, Sukeno A et al (2009) YKL-40 secreted from adipose tissue inhibits degradation of type I collagen[J]. Biochem Biophys Res Commun 388(3):511–516PubMedCrossRef

28.

Bigg HF, Wait R, Rowan AD et al (2006) The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation[J]. J Biol Chem 281(30):21082–21095PubMedCrossRef

29.

Zhu Z, Zheng T, Homer RJ et al (2004) Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation[J]. Science 304(5677):1678–1682PubMedCrossRef

30.

Lee CG, Hartl D, Lee GR et al (2009) Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis[J]. J Exp Med 206(5):1149–1166PubMedPubMedCentralCrossRef

31.

Matsuura H, Hartl D, Kang MJ et al (2011) Role of breast regression protein-39 in the pathogenesis of cigarette smoke-induced inflammation and emphysema[J]. Am J Respir Cell Mol Biol 44(6):777–786PubMedCrossRef

32.

Kanazawa J, Kitazawa H, Masuko H et al (2019) A cis-eQTL allele regulating reduced expression of CHI3L1 is associated with late-onset adult asthma in Japanese cohorts[J]. BMC Med Genet 20(1):58PubMedPubMedCentralCrossRef

33.

Liu L, Zhang X, Liu Y et al (2019) Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations[J]. Respir Res 20(1):95PubMedPubMedCentralCrossRef

34.

Ahangari F, Sood A, Ma B et al (2015) Chitinase 3-like-1 regulates both visceral fat accumulation and asthma-like Th2 inflammation[J]. Am J Respir Crit Care Med 191(7):746–757PubMedPubMedCentralCrossRef

35.

Sohn MH, Lee JH, Kim KW et al (2009) Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy[J]. Am J Respir Crit Care Med 179(6):449–456PubMedCrossRef

36.

Zhu Y, Yan X, Zhai C et al (2017) Association between risk of asthma and gene polymorphisms in CHI3L1 and CHIA: a systematic meta-analysis[J]. BMC Pulm Med 17(1):193PubMedPubMedCentralCrossRef

37.

Ober C, Tan Z, Sun Y et al (2008) Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function[J]. N Engl J Med 358(16):1682–1691PubMedPubMedCentralCrossRef

38.

Cunningham J, Basu K, Tavendale R et al (2011) The CHI3L1 rs4950928 polymorphism is associated with asthma-related hospital admissions in children and young adults[J]. Ann Allergy Asthma Immunol 106(5):381–386PubMedCrossRef

39.

Li K, Chen Z, Qin Y et al (2019) Plasm YKL-40 levels are associated with hypertension in patients with obstructive sleep apnea[J]. Biomed Res Int 2019:5193597PubMedPubMedCentral

40.

Mutlu LC, Tulubas F, Alp R et al (2017) Serum YKL-40 level is correlated with apnea hypopnea index in patients with obstructive sleep apnea syndrome[J]. Eur Rev Med Pharmacol Sci 21(18):4161–4166PubMed

41.

Ragnoli B, Pochetti P, Raie A et al (2021) Interrelationship between obstructive sleep apnea syndrome and severe asthma: from endo-phenotype to clinical aspects[J]. Front Med (Lausanne) 8:640636CrossRef

42.

Peng J, Yu Q, Fan S et al (2021) High blood eosinophil and YKL-40 levels, as well as low CXCL9 levels, are associated with increased readmission in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis 16:795–806PubMedPubMedCentralCrossRef

43.

Hozumi H, Fujisawa T, Enomoto N et al (2017) Clinical utility of YKL-40 in polymyositis/dermatomyositis-associated interstitial lung disease[J]. J Rheumatol 44(9):1394–1401PubMedCrossRef

44.

Yang X, Sheng G (2018) YKL-40 levels are associated with disease severity and prognosis of viral pneumonia, but not available in bacterial pneumonia in children[J]. BMC Pediatr 18(1):381PubMedPubMedCentralCrossRef

45.

Schultz NA, Johansen JS (2010) YKL-40-a protein in the field of translational medicine: a role as a biomarker in cancer patients?[J]. Cancers (Basel) 2(3):1453–1491CrossRef

Title: Association between YKL-40 and asthma: a systematic meta-analysis
Authors: Yihan Jin
Jie Song
Fang Xu
Di Zhang
Jinfang He
Jiakun Zheng
Yanan Zhang
Jintong Li
Yikun Guo
Mengjiao Xu
Xiangfeng Yu
Yanbin Liu
Qinghua Liu
Jun Yan
Publication date: 16-10-2021
Publisher: Springer International Publishing
Keywords: Bronchial Asthma
Chronic Obstructive Lung Disease
Published in: Sleep and Breathing / Issue 3/2022
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-021-02495-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between YKL-40 and asthma: a systematic meta-analysis

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2022

Position-dependent obstructive sleep apnea and its influence on treatment success of mandibular advancement devices

Impact of obstructive sleep apnea on clinical outcomes in patients hospitalized with COVID-19

Sleep duration and health outcomes: an umbrella review

The reproducibility of clinical OSA subtypes: a population-based longitudinal study

Sleepiness in obstructive sleep apnea using hypopneas defined by a 3% oxygen desaturation or arousal but not by 4% or greater oxygen desaturation

The relationship between snoring sounds and EEG signals on polysomnography

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page